Clinical Trial

Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-10; most recent amendment 2025-08-21.
Status change: Not Yet Recruiting → Recruiting 2025-08-21
Trial Details
NCT Number NCT05737342
Lead Sponsor SunWay Biotech Co., LTD.
Conditions High Blood Sugar, Metabolic Syndrome
Enrollment 80 participants
Start Date 2023-04-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-28